AngioDynamics to Present at the J.P. Morgan Healthcare Conference
AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular health and cancer treatment solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jim Clemmer, President and CEO, and Stephen Trowbridge, Executive VP and CFO, will deliver a presentation at the conference on Thursday, January 16, 2025, at 7:30 a.m. PT.
The presentation will be available as a live webcast through the company's investor relations section on their website, with a replay option available after the event. AngioDynamics focuses on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving patient quality of life.
AngioDynamics (NASDAQ: ANGO), un'azienda di tecnologia medica specializzata nella salute vascolare e nelle soluzioni per il trattamento del cancro, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Jim Clemmer, Presidente e CEO, e Stephen Trowbridge, VP Esecutivo e CFO, presenteranno alla conferenza giovedì 16 gennaio 2025, alle 7:30 a.m. PT.
La presentazione sarà disponibile come webcast in diretta nella sezione relazioni con gli investitori del sito web dell'azienda, con la possibilità di rivederla dopo l'evento. AngioDynamics si concentra sul ripristino del flusso sanguigno sano nel sistema vascolare del corpo, sull'espansione delle opzioni di trattamento per il cancro e sul miglioramento della qualità della vita dei pazienti.
AngioDynamics (NASDAQ: ANGO), una empresa de tecnología médica especializada en salud vascular y soluciones para el tratamiento del cáncer, ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. Jim Clemmer, Presidente y CEO, y Stephen Trowbridge, VP Ejecutivo y CFO, realizarán una presentación en la conferencia el jueves 16 de enero de 2025, a las 7:30 a.m. PT.
La presentación estará disponible como una transmisión en vivo a través de la sección de relaciones con inversores en el sitio web de la empresa, con una opción de repetición disponible después del evento. AngioDynamics se enfoca en restaurar un flujo sanguíneo saludable en el sistema vascular del cuerpo, expandir las opciones de tratamiento del cáncer y mejorar la calidad de vida de los pacientes.
AngioDynamics (NASDAQ: ANGO)는 혈관 건강 및 암 치료 솔루션을 전문으로 하는 의료 기술 회사로, 제43회 JP모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. Jim Clemmer 사장 겸 CEO와 Stephen Trowbridge 부사장 겸 CFO는 2025년 1월 16일 목요일 오전 7:30 PT에 컨퍼런스에서 발표를 할 예정입니다.
발표는 회사 웹사이트의 투자자 관계 섹션을 통해 실시간 웹캐스트로 제공되며, 행사 후 재생 옵션도 마련되어 있습니다. AngioDynamics는 신체의 혈관 시스템에서 건강한 혈류를 회복하고, 암 치료 옵션을 확장하며, 환자의 삶의 질을 개선하는 데 중점을 두고 있습니다.
AngioDynamics (NASDAQ: ANGO), une société de technologie médicale spécialisée dans la santé vasculaire et les solutions de traitement du cancer, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Jim Clemmer, Président et CEO, et Stephen Trowbridge, VP Exécutif et CFO, présenteront à la conférence le jeudi 16 janvier 2025, à 7h30 PT.
La présentation sera disponible sous forme de webdiffusion en direct via la section des relations investisseurs sur le site web de l'entreprise, avec une option de rediffusion disponible après l'événement. AngioDynamics se concentre sur la restauration d'un flux sanguin sain dans le système vasculaire du corps, l'expansion des options de traitement du cancer et l'amélioration de la qualité de vie des patients.
AngioDynamics (NASDAQ: ANGO), ein Medizintechnikunternehmen, das sich auf vaskuläre Gesundheit und Lösungen zur Krebsbehandlung spezialisiert hat, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. Jim Clemmer, Präsident und CEO, sowie Stephen Trowbridge, Executive VP und CFO, werden am Donnerstag, den 16. Januar 2025, um 7:30 Uhr PT eine Präsentation auf der Konferenz halten.
Die Präsentation wird als Live-Webcast über den Bereich für Investorenbeziehungen auf der Website des Unternehmens verfügbar sein, mit einer Wiederholungsoption nach der Veranstaltung. AngioDynamics konzentriert sich darauf, den gesunden Blutfluss im vaskulären System des Körpers wiederherzustellen, die Optionen zur Krebsbehandlung zu erweitern und die Lebensqualität der Patienten zu verbessern.
- None.
- None.
A live webcast of the fireside chat will be accessible through the “Investors” section of the Company’s website at www.angiodynamics.com and will be available for replay following the event.
About AngioDynamics, Inc.
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250106392109/en/
Investors:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408
Source: AngioDynamics, Inc.
FAQ
When is AngioDynamics (ANGO) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch AngioDynamics' (ANGO) J.P. Morgan Healthcare Conference presentation?
Which executives will represent ANGO at the 2025 J.P. Morgan Healthcare Conference?
What are the main business focus areas of AngioDynamics (ANGO)?
